Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA. 2013; 110. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology. 1996; 78(8):902-907 111. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse- monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. European Heart Journal. 1998; 19(8):1254-60 112. Ekman I, Fagerberg B, Andersson B, Matejka G, Persson B. Can treatment with angiotensin- converting enzyme inhibitors in elderly patients with moderate to severe chronic heart Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 failure be improved by a nurse-monitored structured care program? A randomized controlled trial. Heart and Lung: Journal of Acute and Critical Care. 2003; 32(1):3-9 113. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of 114. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology. 2010; 56(25):2090-100 115. Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM et al. 